• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Ther Nucleic Acids . A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice

tetano

Editor, Senior Moderator
Mol Ther Nucleic Acids


. 2025 Jun 9;36(3):102594.
doi: 10.1016/j.omtn.2025.102594. eCollection 2025 Sep 9. A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets

Wen-Chien Wang[SUP] 1 [/SUP], Ekramy E Sayedahmed[SUP] 1 [/SUP], Marwa Alhashimi[SUP] 1 [/SUP], Ahmed Elkashif[SUP] 1 [/SUP], Vivek Gairola[SUP] 1 [/SUP], Muralimanohara S T Murala[SUP] 1 [/SUP], Suryaprakash Sambhara[SUP] 2 [/SUP], Suresh K Mittal[SUP] 1 [/SUP]



Affiliations
Abstract

Current seasonal influenza vaccines offer strain-specific protection and, thus, are less effective against mismatched strains. A broadly protective influenza vaccine is desirable to provide comprehensive protection against a wide range of influenza viruses for seasonal and pandemic influenza preparedness. Here, we evaluated the vaccine candidates based on bovine adenoviral (BAd) vectors expressing nucleoprotein (NP) of influenza A (BAd-C5-NP/A) and B (BAd-C5-NP/B) viruses linked to the autophagy-inducing peptide C5 (AIP-C5 or C5) to develop a predominantly T-cell-based vaccine. Robust cellular immune responses and humoral responses were elicited in mice with a single intranasal inoculation. Mice immunized with the BAd Bivalent (BAd-C5-NP/A + BAd-C5-NP/B) vaccine formulation exhibited protective immunity, providing protection against a broad panel of homosubtypic and heterosubtypic influenza A and B viruses, as evidenced by the absence of morbidity and mortality, along with significant reductions in lung viral titers. Protective immunity against seasonal influenza viruses was observed in ferrets following the BAd Bivalent vaccine immunization. These findings support further investigation of the potential of a unique Ad vaccine platform for mucosal immunization expressing NP linked to AIP-C5 as a broadly protective influenza vaccine.

Keywords: MT: Delivery Strategies; autophagy; autophagy-inducing peptide; bovine adenoviral vector; broadly protective influenza vaccine; nonhuman adenoviral vector; nucleoprotein.

 
Back
Top Bottom